Figure 3.

Tumor specific T cell and antibody analysis 10 and 30 days post AOaV-1 administration, respectively. Retro-orbital blood samples were taken 10 days after mice received an i.v. injection of 1 × 10⁸ PFU AOaV-1 or PBS. Red blood cells were lysed, and the remaining cells were stained and analyzed via flow cytometry. Graphed are the number of activated tumor specific TNF-α⁺IFN-γ⁺ CD8⁺ (A) and CD4⁺ (B) T cells in the blood (n = 6 mice per group). (C) Tumor specific antibodies in the serum from treated mice were quantified by flow cytometry and the mean fluorescent intensity (FITC channel) graphed (n = 6 mice per group). AOaV-1, avian orthoavulavirus-1; AAV, Adeno-associated virus; PBS, phosphate-buffered saline mock control group; 3TSR, thrombospondin-1 type I repeats; * p < 0.05; ** p < 0.01; ns = not significant. Error bars denote standard deviation.